IDEXX Laboratories (IDXX) is exhibiting strong financial performance, outperforming competitors and beating earnings expectations. The company has set a new price target at $570.00 by Barclays. Stocks surged 8% on Q4 beats and 44% over strategic inclusion. Partnering with PetDx for Canine Cancer Tests and launching the IDEXX inVue Dx cellular analyzer, IDXX demonstrates innovative strides. Despite insider sales signaling possible caution, investments remain robust with firms like Savant Capital, Kestra Private Wealth Services, and TCG Advisory Services increasing stock positions. However, 2024 outlook was slashed due to unidentified reasons, warranting investor vigilance.
Idexx Laboratories IDXX News Analytics from Thu, 31 Aug 2023 07:00:00 GMT to Thu, 09 May 2024 12:00:36 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
